Literature DB >> 16322377

Consensus statement: medical management of acromegaly.

S Melmed1, F Casanueva, F Cavagnini, P Chanson, L A Frohman, R Gaillard, E Ghigo, K Ho, P Jaquet, D Kleinberg, S Lamberts, E Laws, G Lombardi, M C Sheppard, M Thorner, M L Vance, J A H Wass, A Giustina.   

Abstract

In November 2003, the Pituitary Society and the European Neuroendocrine Association sponsored a consensus workshop in Seville to address challenging issues in the medical management of acromegaly. Participants comprised 70 endocrinologists and neurosurgeons with international expertise in managing patients with acromegaly. All participants participated in the workshop proceedings, and the final document written by the scientific committee reflects the consensus opinion of the interactive deliberations. The meeting was supported by an unrestricted educational grant from Ipsen. No pharmaceutical representatives participated in the program planning or in the scientific deliberations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322377     DOI: 10.1530/eje.1.02036

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  73 in total

1.  Dose optimization of somatostatin analogues for acromegaly patients.

Authors:  A Colao; G Lombardi
Journal:  J Endocrinol Invest       Date:  2010-02       Impact factor: 4.256

2.  Assessment of sleep apnea syndrome in treated acromegalic patients and correlation of its severity with clinical and laboratory parameters.

Authors:  L Vannucci; P Luciani; E Gagliardi; S Paiano; R Duranti; G Forti; A Peri
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

3.  Endoscopic endonasal approach for pituitary adenoma: surgical complications in 301 patients.

Authors:  Jackson A Gondim; Joao Paulo C Almeida; Lucas Alverne F Albuquerque; Michele Schops; Erika Gomes; Tania Ferraz; Wladia Sobreira; Meissa T Kretzmann
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

4.  First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.

Authors:  A Colao; E Martino; P Cappabianca; R Cozzi; M Scanarini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 5.  Somatostatin agonists for treatment of acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Mol Cell Endocrinol       Date:  2007-11-29       Impact factor: 4.102

6.  Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction.

Authors:  Marta Ragonese; Angela Alibrandi; Gianluca Di Bella; Ignazio Salamone; Soraya Puglisi; Oana Ruxandra Cotta; Maria Luisa Torre; Francesco Ferrau; Rosaria Maddalena Ruggeri; Francesco Trimarchi; Salvatore Cannavo
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

7.  Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.

Authors:  E Ghigo; B M K Biller; A Colao; I A Kourides; N Rajicic; R K Hutson; L De Marinis; A Klibanski
Journal:  J Endocrinol Invest       Date:  2009-12-04       Impact factor: 4.256

8.  The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.

Authors:  Laura De Marinis; Antonio Bianchi; Gherardo Mazziotti; Marco Mettimano; Domenico Milardi; Alessandra Fusco; Vincenzo Cimino; Giulio Maira; Alfredo Pontecorvi; Andrea Giustina
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 9.  Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Authors:  A Giustina; A Barkan; P Chanson; A Grossman; A Hoffman; E Ghigo; F Casanueva; A Colao; S Lamberts; M Sheppard; S Melmed
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

10.  Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.

Authors:  A Giustina; T Mancini; P F Boscani; E de Menis; E degli Uberti; E Ghigo; E Martino; F Minuto; A Colao
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.